Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 5;23(15):8716. doi: 10.3390/ijms23158716

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2022 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Influence of Prosigna® results on treatment decision for locally assessed IHC and IHC+G surrogate subtypes. (A) Recommended therapy within locally assessed IHC surrogate subtypes and (B) distribution of Prosigna® subtype within the subset of Luminal A-like IHC subtypes that were recommended towards adjuvant chemotherapy and endocrine therapy. (C) Recommended therapy within locally assessed IHC+G surrogate subtypes and (D) distribution of Prosigna® subtype within the subset of Luminal A-like IHC+G subtypes that were recommended towards adjuvant chemotherapy and endocrine therapy. Colour intensity reflects Prosigna® risk group. IHC = immunohistochemistry; IHC+G = immunohistochemistry + tumor grade; LumA = Luminal A; LumB = Luminal B; Th. = therapy.